NO20024656L - Nukleir faktor kB-induserende faktor - Google Patents

Nukleir faktor kB-induserende faktor

Info

Publication number
NO20024656L
NO20024656L NO20024656A NO20024656A NO20024656L NO 20024656 L NO20024656 L NO 20024656L NO 20024656 A NO20024656 A NO 20024656A NO 20024656 A NO20024656 A NO 20024656A NO 20024656 L NO20024656 L NO 20024656L
Authority
NO
Norway
Prior art keywords
nfif
polypeptides
methods
factor
nfkb
Prior art date
Application number
NO20024656A
Other languages
English (en)
Other versions
NO331972B1 (no
NO20024656D0 (no
Inventor
June Kaplow
Thomas Haws
Marie Rosier
Patrice Denefle
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0018307.9A external-priority patent/GB0018307D0/en
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of NO20024656D0 publication Critical patent/NO20024656D0/no
Publication of NO20024656L publication Critical patent/NO20024656L/no
Publication of NO331972B1 publication Critical patent/NO331972B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO20024656A 2000-03-31 2002-09-27 Nukleinsyre kodende for Nukleaer faktor kB-induserende faktor, protein, ekspresjonsvektor, celle, sammensetning, fremgangsmate for a evaluere forbindelser, anvendelse for fremstilling av et medikament, samt farmasoytisk sammensetning. NO331972B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19390500P 2000-03-31 2000-03-31
GBGB0018307.9A GB0018307D0 (en) 2000-07-26 2000-07-26 Polypeptides
PCT/US2001/010719 WO2001074900A2 (en) 2000-03-31 2001-04-02 Nuclear factor kb inducing factor

Publications (3)

Publication Number Publication Date
NO20024656D0 NO20024656D0 (no) 2002-09-27
NO20024656L true NO20024656L (no) 2002-11-28
NO331972B1 NO331972B1 (no) 2012-05-14

Family

ID=26244722

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20024656A NO331972B1 (no) 2000-03-31 2002-09-27 Nukleinsyre kodende for Nukleaer faktor kB-induserende faktor, protein, ekspresjonsvektor, celle, sammensetning, fremgangsmate for a evaluere forbindelser, anvendelse for fremstilling av et medikament, samt farmasoytisk sammensetning.

Country Status (15)

Country Link
EP (1) EP1290023B1 (no)
JP (1) JP4750999B2 (no)
KR (1) KR100811571B1 (no)
AT (1) ATE486089T1 (no)
AU (1) AU4793101A (no)
CA (1) CA2404688C (no)
DE (1) DE60143354D1 (no)
DK (1) DK1290023T3 (no)
HK (1) HK1053312A1 (no)
IL (3) IL151987A0 (no)
MX (1) MXPA02009481A (no)
NO (1) NO331972B1 (no)
NZ (1) NZ521786A (no)
PT (1) PT1290023E (no)
WO (1) WO2001074900A2 (no)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117534753B (zh) * 2023-12-07 2024-05-10 北京博奥森生物技术有限公司 一种诱导高性能NF-κB多克隆抗体多肽及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0467349B1 (en) 1983-10-20 2000-12-27 The Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition utilizing mRNA interfering complementary RNA
FR2573436B1 (fr) 1984-11-20 1989-02-17 Pasteur Institut Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
CA2108144A1 (en) 1991-03-06 1992-09-07 Jack A. Roth Methods and compositions for the selective inhibition of gene expression
AU3129993A (en) 1991-11-08 1993-06-07 Massachusetts Institute Of Technology Localized oligonucleotide therapy
EP0642589A4 (en) 1992-05-11 1997-05-21 Ribozyme Pharm Inc METHOD AND REAGENT TO INHIBIT VIRAL REPLICATION.
DE69334095T2 (de) 1992-07-17 2007-04-12 Dana-Farber Cancer Institute, Boston Verfahren zur intrazellulären Bindung von zielgerichteten Molekülen
EP0786522A2 (en) 1992-07-17 1997-07-30 Ribozyme Pharmaceuticals, Inc. Enzymatic RNA molecules for treatment of stenotic conditions
EP0905253A3 (en) 1992-12-03 2000-11-02 Genzyme Corporation Adenoviral vector deleted of all E4-ORF except ORF6
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
FR2706486B1 (fr) 1993-06-16 1995-09-01 Rhone Poulenc Rorer Sa Séquences nucléiques, vecteurs les contenant, compositions pharmaceutiques et utilisations thérapeutiques.
DE69435108D1 (de) 1993-07-13 2008-08-14 Centelion Defekte adenovirus-vektoren und deren verwendung in der gentherapie
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
EP0904366A1 (en) * 1996-04-01 1999-03-31 Genentech, Inc. Apo-2li and apo-3 apoptosis polypeptides
US6235512B1 (en) * 1997-07-01 2001-05-22 Tularik Inc. IKK-α proteins, nucleic acids and methods
US7122373B1 (en) * 1998-05-14 2006-10-17 Nuvelo, Inc. Human genes and gene expression products V
US6132964A (en) * 1998-02-06 2000-10-17 Incyte Pharmaceuticals, Inc. Hydrolase enzymes
GB9814036D0 (en) * 1998-06-29 1998-08-26 Univ Dundee Materials and methods relating to the induction of apoptosis in target cells
US6077672A (en) * 1998-08-28 2000-06-20 Isis Pharmaceuticals Inc. Antisense modulation of TRADD expression
CN1302897A (zh) * 1999-10-28 2001-07-11 上海博容基因开发有限公司 一种新的多肽——人酸性鞘磷酯酶相似的磷酸二酯酶21和编码这种多肽的多核苷酸
WO2001053312A1 (en) * 1999-12-23 2001-07-26 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2001077389A2 (en) * 2000-04-05 2001-10-18 Incyte Genomics, Inc. Genes expressed in foam cell differentiation
WO2001094629A2 (en) * 2000-06-05 2001-12-13 Avalon Pharmaceuticals Cancer gene determination and therapeutic screening using signature gene sets

Also Published As

Publication number Publication date
DE60143354D1 (de) 2010-12-09
IL151987A0 (en) 2003-04-10
CA2404688C (en) 2012-07-31
JP2003529360A (ja) 2003-10-07
DK1290023T3 (da) 2011-02-14
KR100811571B1 (ko) 2008-03-10
AU4793101A (en) 2001-10-15
MXPA02009481A (es) 2004-05-14
WO2001074900A2 (en) 2001-10-11
WO2001074900A9 (en) 2003-03-06
JP4750999B2 (ja) 2011-08-17
IL198132A0 (en) 2011-08-01
EP1290023A2 (en) 2003-03-12
PT1290023E (pt) 2011-01-05
KR20020087459A (ko) 2002-11-22
WO2001074900A3 (en) 2002-05-02
HK1053312A1 (en) 2003-10-17
ATE486089T1 (de) 2010-11-15
NO331972B1 (no) 2012-05-14
IL151987A (en) 2010-12-30
EP1290023B1 (en) 2010-10-27
NO20024656D0 (no) 2002-09-27
NZ521786A (en) 2004-07-30
CA2404688A1 (en) 2001-10-11

Similar Documents

Publication Publication Date Title
SE9800836D0 (sv) New Compounds
CY1120241T1 (el) Χρησιμοποιηση εψιδινης για την παρασκευη ενος φαρμακου για τη θεραπεια διαταραχων της ομοιοστασης του σιδηρου
TR200103233T2 (tr) Antikolinerjik etkili bileşik ve ß-mimetikler bazında yeni ilaç bileşimleri.
ATE232396T1 (de) Oxydiertes thymosin beta 4
SE9704644D0 (sv) New use
FR2834889B1 (fr) Forme pharmaceutique solide orodispersible
ITMI20011057A0 (it) Preparazione ed uso di peptidi ciclici e ramificati e loro deriati marcati come agenti terapeutici agonisti o antagonisti della colecistochi
NO20024656L (no) Nukleir faktor kB-induserende faktor
DK1353948T3 (da) Oplöselige biologiske analoge til bata-amyloidpeptid
EE200300328A (et) IL-18 inhibiitorite kasutamine südamehaiguse raviks ja/või ennetamiseks
NO995692D0 (no) Nye BPC-peptidsalter med organbeskyttende aktivitet, metoden for deres fremstilling og deres anvendelse
CY1106363T1 (el) Χρηση του ενepγοποιημενου παραγοντα πηξης vii για την αγωγη των επαγομενων απο θρομβολυτικη θepαπεια μειζονων αιμορραγιων
ATE277639T1 (de) Zusammensetzungen von adenosin a1 agonisten und 5ht3 agonisten
BR0109721A (pt) Fator de indução do fator kb nuclear
AP2003002795A0 (en) Oxidized proteins their biological activity and therapeutic and diagonistic measures which are derived from the active mechanism from the use of theseproteins or from the inhibition thereof
DE50208267D1 (de) Wirkstoff-kombination zur medikamentösen therapie der nikotinabhängigkeit
ATE253555T1 (de) Vitamin d-analogen und ihre pharmazeutische verwendung
SE9803158D0 (sv) A new composition
Chen et al. Endothelial cell integrin beta4 knockout attenuates LPS-induced murine acute lung injury
ITLI20020003A1 (it) Custodia per totanaia e simili idonea alla sicurezza antinfortunistica del pescatore e ad un uso facile di attrezzi da pesca
IT1294932B1 (it) Uso di 2-amminotetraline-6,7 sostituite per la preparazione di composizioni farmaceutiche atte al trattamento di patologie
DE10294405D2 (de) Verwendung von Interfernon-beta zur Therapie des systemischen Lupus erythematodes
IT1318534B1 (it) Metodo per misurare caratteristiche meccaniche totali e regionali delsistema respiratorio umano.
WO1999037774A8 (en) Differentiation-associated sequences and methods of use therefor
ATE397755T1 (de) Diagnostik- und therapie- verfahren von mit dopaminrezeptor d3 (drd3) verbundenen krankheiten

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees